Subscribe to RSS
DOI: 10.1016/j.homp.2009.02.002
Isopathic versus enantiomeric inhibition of U-50488 HCl toxicity – experimental studies
Subject Editor:
Publication History
Received14 September 2008
revised01 February 2009
accepted11 February 2009
Publication Date:
15 December 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00034926/200902/lookinside/thumbnails/10-1016-j-homp-2009-02-002-1.jpg)
Background: Previous studies have investigated toxicity inhibition of optically active compounds by potentized preparations of their enantiomers. It was hypothesised that inhibition of toxicity may be stereospecific. This paper presents 2 studies investigating stereoisomer potencies in terms of their ability to counteract toxicity of the (−) stereoisomer. The stereoisomers used were (−)-trans-(1S,2S)-U-50488 HCl and (+)-trans-(1R,2R)-U-50488 HCl.
Materials & methods: Designs were prospective, blind, randomised, intention-to-treat and compared the efficacy of 2 indistinguishable treatments. The outcome was the difference in survival. Potency ‘chords’ consisting of 4th, 12th and 30th approximately centesimal dilutions were prepared, representing concentrations of 1.08 × 10−10 M. One study compared inhibition of (−)-U-50488 toxicity injected ip at the estimated LD50 into male ICR mice, treated with a potency chord of the same stereoisomer, with control (‘isopathic’ study). The other study compared inhibition of toxicity by potency chords made from the stereoisomers (+)-U-50488 and (−)-U-50488 (‘enantiomer’ study), Treatments were administered orally on 11 occasions: twice before and nine times after ip injections.
Results: The isopathic study did not yield a significant result. In the enantiomer study, comparison of isopathy with enantiomer potency treatment showed a highly significant difference odds ratio 1.97 (95% CI: 1.23–3.14).
Conclusion: We conclude that enantiomeric potencies are superior to identically produced isopathic potencies, in inhibiting toxicity of (−)-U-50488 HCl. Homeopathic inhibition of toxicity may be stereospecific.
-
References
- 1 Joshi S.K., Gebhart G.F. Nonopioid actions of U50,488 enantiomers contribute to their peripheral cutaneous antinociceptive effects. J Pharmacol Exp Ther 2003; 305: 919-924.
- 2 Su X., Joshi S.K., Kardos S., Gebhart G.F. Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects. J Neurophysiol 2002; 87: 1271-1279.
- 3 Kuzeff R.M., Topashka-Ancheva M.N., Mecheva R.P. Inhibition of (-)-trans-(1S,2S)-U50488 hydrochloride by its enantiomer in white mice – a placebo-controlled, randomized study. Forsch Komplementarmed Klass Naturheilkd 2004; 11: 144-149.
- 4 Desu M.M., Raghavarao D. Nonparametric Statistical Methods for Complete and Censored Data. Boca Raton, Florida: Chapman & Hall/CRC; 2004.
- 5 Kuzeff R.M. Treatment of Effect of Chemicals with their Ultradilute Stereoisomers. International Patent Application No.: PCT/AU2003/000219 Applicant Sempach Pty Ltd; 2003.
- 6 Kozlova O., Zwinderman M., Christofi N. A new short-term toxicity assay using Aspergillus awamori with recombidant aequorin gene. BMC Microbiol 2005 Jul 2; 5: 50
- 7 Kuzeff, R.M. Method of Treatment. Australian Innovation patent 2008101117, filed 17 November 2008.
- 8 Kuzeff, R.M. Method of Treatment. International PCT/AU2008/001611, filed 3 November 2008.
- 9 Kuzeff R.M., Topashka-Ancheva M.N., Mecheva R.P. Inhibition of (-)-propranolol hydrochloride by its enantiomer in white mice. Forsch Komplementarmed Klass Naturheilkd 2003; 10: 309-314.
- 10 Kuzeff R.M., Mecheva R.P., Topashka-Ancheva M.N. Inhibition of (-)-propranolol hydrochloride by its enantiomer in white mice–a placebo-controlled randomized study. Forsch Komplementarmed Klass Naturheilkd 2004; 11: 14-19.
- 11 Biologische Heilmittel Heel GmbH. Biotherapeutic Index. Baden-Baden, 2000.
- 12 Weiser M., Gegenheimer L.H., Klein P. A randomized equivalence trial comparing the efficacy and safety of Luffa comp. -Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis. Forsch Komplementarmed 1999 Jun; 6 (03) 142-148.
- 13 Whittow G.C. Comparative Physiology of Thermoregulation – Mammals 2, Minimal Metabolism and Body Size . 1971. New York: Academic Press; 30-36
- 14 Smith H.J. Introduction to the Principles of Drug Design and Action . 2006. Boca Raton: CRC Press; ISBN: 0-415-28877-0 117-183 Chapter 6
- 15 Cazin J.C., Cazin M., Gaborit J.L. et al. A study of the effect of decimal and centesimal dilutions of arsenic on the retention and mobilization of arsenic in the rat. Hum Toxicol 1987; 6: 315-320.
- 16 Fisher P., House I., Belon P., Turner P. The influence of the homoeopathic remedy plumbum metallicum on the excretion kinetics of lead in rats. Hum Toxicol 1987; 6: 321-324.
- 17 Jonas W., Lin Y., Tortella F. Neuroprotection from glutamate toxicity with ultra-low dose glutamate. Neuroreport 2001; 12: 335-339.
- 18 Jonas W.B. Do homeopathic nosodes protect against infection? An experimental test. Altern Ther Health Med 1999; 5: 36-40.
- 19 Aabel S., Laerum E., Dølvic S., Djupesland P. Is homeopathic ‘immunotherapy’ effective? A double-blind, placebo-controlled trial with the isopathic remedy Betula 30c for patients with birch pollen allergy. Br Homeopath J 2000 Oct; 89 (04) 161-168.
- 20 Aabel S. No beneficial effect of isopathic prophylactic treatment for birch pollen allergy during a low-pollen season: a double-blind, placebo-controlled clinical trial of homeopathic Betula 30c. Br Homeopath J 2000 Oct; 89 (04) 159-160.
- 21 Berchieri Jr. A., Turco W.C., Paiva J.B., Oliveira G.H., Sterzo E.V. Evaluation of isopathic treatment of Salmonella enteritidis in poultry. Homeopathy 2006 Apr; 95 (02) 94-97.
- 22 Velkers F.C., te Loo A.J., Madin F., van Eck J.H. Isopathic and pluralist homeopathic treatment of commercial broilers with experimentally induced colibacillosis. Res Vet Sci 2005 Feb; 78 (01) 77-83.
- 23 de Almeida L.R., Campos M.C., Herrera H.M., Bonamin L.V., da Fonseca A.H. Effects of homeopathy in mice experimentally infected with Trypanosoma cruzi. Homeopathy 2008 Apr; 97 (02) 65-69.
- 24 Bonamin L.V., Martinho K.S., Nina A.L., Caviglia F., Do rio R.G. Very high dilutions of dexamethaxone inhibit its pharmacological effects in vivo. Br Homeopath J 2001 Oct; 90 (04) 198-203.